{"name":"Acacia Pharma Ltd","slug":"acacia-pharma-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"immunology","drugs":[{"name":"APD209","genericName":"APD209","slug":"apd209","indication":"Other","status":"phase_2"},{"name":"APD405","genericName":"APD405","slug":"apd405","indication":"Other","status":"phase_2"},{"name":"APD421- Amisulpride for IV injection","genericName":"APD421- Amisulpride for IV injection","slug":"apd421-amisulpride-for-iv-injection","indication":"Prevention of postoperative nausea and vomiting (PONV)","status":"phase_3"},{"name":"14C-APD421","genericName":"14C-APD421","slug":"14c-apd421","indication":"Other","status":"phase_1"},{"name":"APD421","genericName":"APD421","slug":"apd421","indication":"Chemotherapy-induced nausea and vomiting (CINV)","status":"phase_3"},{"name":"APD515","genericName":"APD515","slug":"apd515","indication":"Chemotherapy-induced nausea and vomiting (CINV)","status":"phase_2"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Amisulpride IV","genericName":"Amisulpride IV","slug":"amisulpride-iv","indication":"Schizophrenia","status":"phase_1"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"APD403 oral","genericName":"APD403 oral","slug":"apd403-oral","indication":"Prevention of postoperative shivering","status":"phase_2"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"APD403 IV","genericName":"APD403 IV","slug":"apd403-iv","indication":"Prevention and treatment of shivering and hypertension during anesthesia","status":"phase_2"}]}],"pipeline":[{"name":"Amisulpride IV","genericName":"Amisulpride IV","slug":"amisulpride-iv","phase":"phase_1","mechanism":"Dopamine D2/D3 receptor antagonist","indications":["Schizophrenia"],"catalyst":""},{"name":"APD209","genericName":"APD209","slug":"apd209","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"APD403 oral","genericName":"APD403 oral","slug":"apd403-oral","phase":"phase_2","mechanism":"APD403 is a selective α2δ-1 subunit ligand.","indications":["Prevention of postoperative shivering"],"catalyst":""},{"name":"APD405","genericName":"APD405","slug":"apd405","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"APD421- Amisulpride for IV injection","genericName":"APD421- Amisulpride for IV injection","slug":"apd421-amisulpride-for-iv-injection","phase":"phase_3","mechanism":"APD421 is an intravenous formulation of amisulpride, a dopamine D2/D3 receptor antagonist that blocks dopamine signaling to prevent postoperative nausea and vomiting.","indications":["Prevention of postoperative nausea and vomiting (PONV)"],"catalyst":""},{"name":"14C-APD421","genericName":"14C-APD421","slug":"14c-apd421","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"APD403 IV","genericName":"APD403 IV","slug":"apd403-iv","phase":"phase_2","mechanism":"APD403 IV is an anesthetic agent that works by blocking N-methyl-D-aspartate (NMDA) receptors.","indications":["Prevention and treatment of shivering and hypertension during anesthesia"],"catalyst":""},{"name":"APD421","genericName":"APD421","slug":"apd421","phase":"phase_3","mechanism":"APD421 is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the chemoreceptor trigger zone and vomiting center.","indications":["Chemotherapy-induced nausea and vomiting (CINV)","Postoperative nausea and vomiting (PONV)"],"catalyst":""},{"name":"APD515","genericName":"APD515","slug":"apd515","phase":"phase_2","mechanism":"APD515 is a selective antagonist of the neurokinin-1 (NK1) receptor that reduces nausea and vomiting by blocking substance P signaling in the chemoreceptor trigger zone and vomiting center.","indications":["Chemotherapy-induced nausea and vomiting (CINV)","Postoperative nausea and vomiting (PONV)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNU1NubXZRbUhvOFd5SnNxbFR1UkV3aGRUX1FIZ0FVZ2J1YzZkMXlpUmFaR0ZrbjVuN2Z6emdZYWlWVmJoMVMwczhPRG5ZdXc5V1FNNXd4ODN0OFRTNGtfYkFOUzNZNFNKbWU1Q0U3N2cxb2pHNTJNcU5wbVYwejRBUHRDX0Vpd2M2a2RTbER0eU91OW8?oc=5","date":"2026-03-27","type":"pipeline","source":"openPR.com","summary":"Segmentation, Major Trends, and Competitive Overview of the Cancer Supportive Care Products Market - openPR.com","headline":"Segmentation, Major Trends, and Competitive Overview of the Cancer Supportive Care Products Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOd05SN1hIYVZvUWNTTENzV1QyZzNJSVZYOVA0aXJPcVNUR2doUnE4MUNVVFg4bHZBTVRlbklUUkxaV2VNOFpkT1NNRnIwQUpFM3M1RWJVYXBEQ2syV0lzckpyaHo0cnp3S0lmU3JtNmhFUjZBUHN4Y29DWmM5c2VYR1d3RFlQajBOb2V3djN3ZlNrVXBMUjROWFZqa1V5YklY?oc=5","date":"2026-01-14","type":"pipeline","source":"Yahoo Finance","summary":"Eagle Pharmaceuticals Announces Divestiture of Barhemsys - Yahoo Finance","headline":"Eagle Pharmaceuticals Announces Divestiture of Barhemsys","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNM09tOFZoZXU0WXpWUU9fMlc4a1hTMkRRWHNZT3hYcF9oY3BoLVJ2a25rNm9IM0g5dm1pRzkzbHNQNDJrX1NsQ1FfZTd1ZnhXbDZTN1FPNTlvd1pVUkhWM2owRmgzWWhTOC1XMktQc19rYzZIdTY0UzZTN2JpeE02ME1DSTNqZW1rNkpzd2JEWjBEVXR4UUtBQ21kNUxpRGdRV1lJ?oc=5","date":"2026-01-14","type":"regulatory","source":"Stock Titan","summary":"Only FDA-approved post-surgery nausea drug shifts to new owner - Stock Titan","headline":"Only FDA-approved post-surgery nausea drug shifts to new owner","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQUkZOamtWZmZmcHBIWmZiSHFEVnN0SlpZUktsZW9NMmk1RTZfaXRqVUNkSzJQY2lUaU1OSk9ualh5ZVFNYnZIUDYyRy1uUE9DM3k3MDVjN2xnWlFMTnBwQ01WbHNZOUpnTC1vdEFjVVktRks1eUxYdTBvajFGdkVZSUZPQUlhQUlheE45TlVkSkdpakk2d0MxOWo4TG5KZS1waWc?oc=5","date":"2025-10-15","type":"earnings","source":"Yahoo Finance","summary":"Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements - Yahoo Finance","headline":"Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPTlhVdi1pNGJfSG1lQ3EwSVdwS1l2M05ET1hlSDV0X0FmbkNOZ0U0dEhoV1pFWXh5Z0htT19qaG15QmhUVEFSZVp0SVhWUUo4Y052ZVVHQ2V6dG41NWRNajBCYmhGMkVIUEdpM1doaW1ISzVCQUJNY0JKMEVBaXhjbzEzUkE3dWN6YnVqY1ZWNjByWV9Ta0c0SXpKV1ZOUTNUaVhIRG9CSjVfWmVvRTYzT1JnLXdzYVJJOGc?oc=5","date":"2025-10-06","type":"earnings","source":"Stock Titan","summary":"Q1 2025 Unaudited Financials — Eagle Pharmaceuticals posts statements and investor materials available now - Stock Titan","headline":"Q1 2025 Unaudited Financials — Eagle Pharmaceuticals posts statements and investor materials available now","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5rUWFuZXRreHh0eVMwRmV2ZEZYd0JjcjRubTlwUHFITUp4LWFYSjZjQldfRWJ1aVRuakhGYWtmSE50QklnN3czTkdRY2pwNDN5dFZB?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"EGRX Stock Price, News & Analysis - Stock Titan","headline":"EGRX Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQTmNfVzI2OTNIQ3Jyb2xXaVo3dHJKQWRrYi0wbUprN1Ryai15MWNGLUZlU3gwLXhDNHJoN1RaQ2E5YzM0dktHSGFncUc4LUYxaHg5aW91cWw2ZS0zeENzdTU1VHQtWERzVU9aU2hxcWpJVnRQMDRwakN3d1pTME1HNTllREN5cDdUOUdMTTZzaV90RUwwNXR5QzRBNWk0aEk?oc=5","date":"2023-11-29","type":"pipeline","source":"citybiz","summary":"Eagle Pharmaceuticals CEO and Founder Scott Tarriff Retires - citybiz","headline":"Eagle Pharmaceuticals CEO and Founder Scott Tarriff Retires","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxObVRWOWtDeVJia3F3S2NiN2JLQ0Y3dXhfcktaOUx0MFFhVEpCTXY4N3hNNERPN25sbXdLUXVKRURpNjhrTzRYdzFxRXllM3dlOWJ2dGMxek5wV2k5ZlhVdGtEcFdvSWFyb0NzZEI0VTdRVHRtM0lMbUtjendvR3RpVnpxOG93Yl9wTnM3Q0JWTmVzR1dRcDliNzVES0FJeTBhb3Z1MjNJb0JwQnVpYnZ3MDNhelNEdw?oc=5","date":"2023-10-23","type":"pipeline","source":"BioSpace","summary":"Eagle Pharmaceuticals Granted Unique J-Code and Pass-Through Status for BARHEMSYS® from CMS - BioSpace","headline":"Eagle Pharmaceuticals Granted Unique J-Code and Pass-Through Status for BARHEMSYS® from CMS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNajI1TXFHN29WUUJEbDROdUJ0SUlYOEVaMFRDT084bGZNVjlpWUJ4U0xZYjZmdHN2a0ttclRFbXNvaldHeXZ2SFljVmRkOE11akVUaUNfc3pUeS1HVThYaUNQV21pWjNIRmkyaC1GQkZSbGR1akE3bzMzU1FWV1BfVHFIbTZvLTlhQXVmTUs3MFdxWFBVVWRGRGJieGYtTjNTUzRYWWRkeUxHakp4TVdjejUzMjh2Zw?oc=5","date":"2022-03-31","type":"pipeline","source":"Cambridge Independent","summary":"Acacia is valued at €94.7m in sale to Eagle Pharmaceuticals - Cambridge Independent","headline":"Acacia is valued at €94.7m in sale to Eagle Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxObGc1MFVfbV93aXRfNEYzMGR0all6TFRKWFV4aURVZGFxWXgxamxIbE9vLUEtQV82V2NZeVdFbXZCOHRkbTRQa1BHWmNHVWlmTnlYUGNjV1hibU1fT3BvWEZ5NWVqV29KY0VTZHJBal94MHJpUEY4VnJBem9MZzlJVnoxM2F5WWROTWE2NDVoNHZHNGwwZzBBaGF4M2xsNXZSd0dkcWtMODBlUldLMGdyYl8zTEVXRTVLcWZwcF9EeWdlcHl0TzF2R05FLWlpZlI1NS1raThoUFpBVDcx?oc=5","date":"2022-03-28","type":"deal","source":"globenewswire.com","summary":"Eagle Pharmaceuticals Agrees to Terms to Acquire Acacia Pharma Group plc - globenewswire.com","headline":"Eagle Pharmaceuticals Agrees to Terms to Acquire Acacia Pharma Group plc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOWWZtWjhhRWNOMk8tWm9oV1cycHVVQXlQdTNCNzF5cUVzeTNyU3RfNTdZRUpLdjBNdHMxdnZFQlRvb2dKaEp5WTZfM0d2QTVzS29ORERVSjBUamNONk5UX0NjM1YzbkZuWElRTUkyVXJnYnBNek1SdEZUVmZEYzZTSU1SbGt1TUZvTzhfdlF4R0ZmOUFTQmFXUkM4Smk?oc=5","date":"2020-02-28","type":"regulatory","source":"PMLiVE","summary":"Acacia finally gets FDA okay for first product Barhemsys - PMLiVE","headline":"Acacia finally gets FDA okay for first product Barhemsys","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxOM0JQUnQ5OTNNUDlJUmRtTXJGbEQ0V0RvZDZ2WnZkQzJmV1E0VV8ydTMwRThYOVNhVmkzUFg1aXRrNi1ONEFGZEJIRUNWcElOSFI2VlRHa3JpR2ZqTmdXMjBIMDhmUmlrU3haUFV6X05CWVZOOF9hVzRvMEZoTTBFUlFXbkdQUTRfVGxLUGhhd3RFaXdhdDR1SUI1VDhIR05GNUxBSDhaM1RCMDVGTmlrOThWRUFIMGh3TmNKTURiTl91c0dHeHZfMnRqTEdRVEltQ2FOcGp3cTI4LXFyVWRwaUtOaVVjdnRsQUxVXy1Fb1k2c1ZPc2tPNkt6bXA2M3hOandn?oc=5","date":"2017-11-15","type":"pipeline","source":"PR Newswire","summary":"Outpost Medicine Appoints Scott Byrd as Chief Executive Officer and Raises $20 Million in Series A Financing Extension - PR Newswire","headline":"Outpost Medicine Appoints Scott Byrd as Chief Executive Officer and Raises $20 Million in Series A Financing Extension","sentiment":"neutral"}],"patents":[],"drugCount":9,"phaseCounts":{"phase_1":2,"phase_2":5,"phase_3":2},"enrichmentLevel":2,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}